Metabolic Syndrome and Elevated C-Reactive Protein in Breast Cancer Survivors on Adjuvant Hormone Therapy
Publication: Journal of Women's Health
Volume 18, Issue Number 12
Abstract
Aims: As the efficacy of treatment for breast cancer has improved, particularly with the use of antiestrogenic therapies, there is an increasing population of long-term breast cancer survivors who seeks care with unique health issues. These patients may be at increased risk for cardiovascular disease (CVD) resulting from excess adiposity and treatment effects. Metabolic syndrome (MetS) and elevated C-reactive protein (CRP), two predictors of CVD, have not been fully evaluated in overweight breast cancer survivors on hormone-modulating agents.
Methods: Anthropometric measures, including weight, height, waist and hip circumferences; clinical laboratory assessments, including lipids, glucose, glycoslyated hemoglobin (HbA1c), insulin, and high sensitivity CRP; and body composition and blood pressure (BP) were collected from overweight breast cancer survivors (n = 42). Select measures were used to derive MetS using the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) diagnostic criteria.
Results: Participants had a mean body weight of 83.8 kg and body mass index (BMI) of 31.4 kg/m2. Mean fasting glucose (98 ± 12.9 mg/dL), HbA1c (6.0 ± 0.5 mg/dL), cholesterol (199 ± 33.7 mg/dL), and insulin (16 ±13.2 mg/dL) were all at the upper end of the normal range. MetS was diagnosed in 54.8% of overweight postmenopausal breast cancer survivors. CRP was moderately or severely elevated in 90.5% of the population (mean of 5.1 ± 5.3 mg/dL).
Conclusions: In our sample, overweight breast cancer survivors commonly have MetS and elevated CRP that place them at increased risk for cardiovascular and other metabolic diseases. If replicated in a larger sample, this warrants close medical monitoring to prevent and reduce morbidity and mortality unrelated to breast cancer.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Carmichael AR. Obesity and prognosis of breast cancerObes Rev20067333-340. 1. Carmichael AR. Obesity and prognosis of breast cancer. Obes Rev 2006;7:333–340.
2.
Newman SCLees AWJenkins HJ. The effect of body mass index and oestrogen receptor level on survival of breast cancer patientsInt J Epidemiol199726484-490. 2. Newman SC, Lees AW, Jenkins HJ. The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol 1997;26:484–490.
3.
Zhang SFolsom ARSellers TAKushi LHPotter JD. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health StudyCancer199576275-283. 3. Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study. Cancer 1995;76:275–283.
4.
Hebert JRAugustine ABarone JKabat GCKinne DWWynder EL. Weight, height and body mass index in the prognosis of breast cancer: Early results of a prospective studyInt J Cancer198842315-318. 4. Hebert JR, Augustine A, Barone J, Kabat GC, Kinne DW, Wynder EL. Weight, height and body mass index in the prognosis of breast cancer: Early results of a prospective study. Int J Cancer 1988;42:315–318.
5.
Kroenke CHChen WYRosner BHolmes MD. Weight, weight gain, and survival after breast cancer diagnosisJ Clin Oncol2005231370-1378. 5. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005;23:1370–1378.
6.
Demark-Wahnefried WRimer BKWiner EP. Weight gain in women diagnosed with breast cancerJ Am Diet Assoc199797519-526529. 6. Demark-Wahnefried W, Rimer BK, Winer EP. Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 1997;97:519–526, 529.
7.
Rock CLDemark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: A review of the evidenceJ Clin Oncol2002203302-3316. 7. Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: A review of the evidence. J Clin Oncol 2002;20:3302–3316.
8.
Grundy SM. Metabolic syndrome pandemicArterioscler Thromb Vasc Biol200828629-636. 8. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629–636.
9.
Grundy SMBrewer HB JrCleeman JISmith SC JrLenfant CNational Heart, Lung, and Blood Institute, American Heart Association. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definitionCirculation2004109433-438. 9. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, National Heart, Lung, and Blood Institute, American Heart Association. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433–438.
10.
Heikkilä KEbrahim SRumley ALowe GLawlor DA. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: Findings from the British Women's Heart and Health StudyCancer Epidemiol Biomarkers Prev200716155-159. 10. Heikkilä K, Ebrahim S, Rumley A, Lowe G, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: Findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev 2007;16:155–159.
11.
McMillan DCElahi MMSattar NAngerson WJJohnstone JMcArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and noncancer survival in patients with cancerNutr Cancer20014164-69. 11. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and noncancer survival in patients with cancer. Nutr Cancer 2001;41:64–69.
12.
Pasanisi PBerrino FDe Petris MVenturelli EMastroianni APanico S. Metabolic syndrome as a prognostic factor for breast cancer recurrencesInt J Cancer2006119236-238. 12. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006;119:236–238.
13.
Al Murri AMWilson CLannigan A et al. Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancerBr J Cancer200796891-895. 13. Al Murri AM, Wilson C, Lannigan A, et al. Evaluation of the relationship between the systemic inflammatory response and cancer-specific survival in patients with primary operable breast cancer. Br J Cancer 2007;96:891–895.
14.
Rose DPKomninou DStephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancerObes Rev20045153-165. 14. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 2004;5:153–165.
15.
Nguyen MCStewart RBBanerji MAGordon DHKral JG. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancerInt J Obes Rel Metab Disord200125296-298. 15. Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Rel Metab Disord 2001;25:296–298.
16.
Cushman MCostantino JPTracy RP et al. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effectArterioscler Thromb Vasc Biol200121255-261. 16. Cushman M, Costantino JP, Tracy RP, et al. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001;21:255–261.
17.
Braithwaite RSChlebowski RTLau JGeorge SHess RCol NF. Meta-analysis of vascular and neoplastic events associated with tamoxifenJ Gen Intern Med200318937-947. 17. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937–947.
18.
Hozumi YKawano MHakamata YMiyata MJordan VC. Tamoxifen inhibits lipoprotein activity: In vivo and in vitro studiesHorm Res20005336-39. 18. Hozumi Y, Kawano M, Hakamata Y, Miyata M, Jordan VC. Tamoxifen inhibits lipoprotein activity: In vivo and in vitro studies. Horm Res 2000;53:36–39.
19.
Grainger DJSchofield PM. Tamoxifen for the prevention of myocardial infarction in humans: Preclinical and early clinical evidenceCirculation20051123018-3024. 19. Grainger DJ, Schofield PM. Tamoxifen for the prevention of myocardial infarction in humans: Preclinical and early clinical evidence. Circulation 2005;112:3018–3024.
20.
McCloskey EVHannon RALakner G et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal womenEur J Cancer2007432523-2531. 20. McCloskey EV, Hannon RA, Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007;43:2523–2531.
21.
Chapman JAMeng DShepherd L et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancerJ Natl Cancer Inst2008100252-260. 21. Chapman JA, Meng D, Shepherd L, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 2008;100:252–260.
22.
Ponzone RMininanni PCassina EPastorino FSismondi P. Aromatase inhibitors for breast cancer: Different structures, same effects?Endocr Rel Cancer20081527-36. 22. Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P. Aromatase inhibitors for breast cancer: Different structures, same effects? Endocr Rel Cancer 2008;15:27–36.
23.
Coates ASKeshaviah AThürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98J Clin Oncol200725486-492. 23. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25:486–492.
24.
Giordano SHHortobagyi GN. Time to remove the subspecialty blinders: Breast cancer does not exist in isolationJ Natl Cancer Inst2008100230-231. 24. Giordano SH, Hortobagyi GN. Time to remove the subspecialty blinders: Breast cancer does not exist in isolation. J Natl Cancer Inst 2008;100:230–231.
25.
Lohman TGRoche AFMartorell RAnthropometric standardization reference manualChampaign, ILHuman Kinetics Books1988. 25. Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign, IL: Human Kinetics Books, 1988.
26.
Pierce JPFaerber SWright FA et al. A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: The Women's Healthy Eating and Living (WHEL) StudyControl Clin Trials200223728-756. 26. Pierce JP, Faerber S, Wright FA, et al. A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: The Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials 2002;23:728–756.
27.
Compher CHise MSternberg AKinosian BP. Comparison between MedGem and Deltatrac resting metabolic rate measurementsEur J Clin Nutr2005591136-1141. 27. Compher C, Hise M, Sternberg A, Kinosian BP. Comparison between MedGem and Deltatrac resting metabolic rate measurements. Eur J Clin Nutr 2005;59:1136–1141.
28.
Martínez MEMarshall JRGraver E et al. Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrenceCancer Epidemiol Biomarkers Prev19998941-946. 28. Martínez ME, Marshall JR, Graver E, et al. Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. Cancer Epidemiol Biomarkers Prev 1999;8:941–946.
29.
Ainsworth BEHaskell WLWhitt MC et al. Compendium of physical activities: An update of activity codes and MET intensitiesMed Sci Sports Exerc200032SupplS498-S516. 29. Ainsworth BE, Haskell WL, Whitt MC, et al. Compendium of physical activities: An update of activity codes and MET intensities. Med Sci Sports Exerc 2000;32(Suppl):S498–S516.
30.
Staten LKTaren DLHowell WH et al. Validation of the Arizona Activity Frequency Questionnaire using doubly labeled waterMed Sci Sports Exerc2001331959-1967. 30. Staten LK, Taren DL, Howell WH, et al. Validation of the Arizona Activity Frequency Questionnaire using doubly labeled water. Med Sci Sports Exerc 2001;33:1959–1967.
31.
Grundy SMCleeman JIDaniels SR et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statementCirculation20051122735-2752. 31. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735–2752.
32.
Good CKHolschuh NAlbertson AMEldridge AL. Whole grain consumption and body mass index in adult women: An analysis of NHANES 1999–2000 and the USDA Pyramid Servings DatabaseJ Am Coll Nutr20082780-87. 32. Good CK, Holschuh N, Albertson AM, Eldridge AL. Whole grain consumption and body mass index in adult women: An analysis of NHANES 1999–2000 and the USDA Pyramid Servings Database. J Am Coll Nutr 2008;27:80–87.
33.
Rifai NRidker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: Implication for clinical interpretationClin Chem200349666-669. 33. Rifai N, Ridker PM. Population distributions of C-reactive protein in apparently healthy men and women in the United States: Implication for clinical interpretation. Clin Chem 2003;49:666–669.
34.
Thompson PAStopeck ATAlberts DHess L. Breast cancer preventionFundamentals of cancer preventionNew YorkSpringer-Verlag2008347-376. 34. Thompson PA, Stopeck AT. Breast cancer prevention. In: Alberts D, Hess L, eds. Fundamentals of cancer prevention. New York: Springer-Verlag, 2008:347–376.
35.
Taggu WLloyd G. Treating cardiovascular disease in womenMenopause Int200713159-164. 35. Taggu W, Lloyd G. Treating cardiovascular disease in women. Menopause Int 2007;13:159–164.
36.
Ford ES. Prevalence of the metabolic syndrome in U.S. populationsEndocrinol Metab Clin North Am200433333-350. 36. Ford ES. Prevalence of the metabolic syndrome in U.S. populations. Endocrinol Metab Clin North Am 2004;33:333–350.
37.
Toniolo PGLevitz MZeleniuch-Jacquotte A et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal womenJ Natl Cancer Inst199587190-197. 37. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190–197.
38.
Rock CLFlatt SWLaughlin GA et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancerCancer Epidemiol Biomarkers Prev200817614-620. 38. Rock CL, Flatt SW, Laughlin GA, et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:614–620.
39.
Beaulieu LMWhitley BRWiesner TF et al. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycleBioEssays2007291029-1038. 39. Beaulieu LM, Whitley BR, Wiesner TF, et al. Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. BioEssays 2007;29:1029–1038.
40.
Bansal SRidker PM. Comparison of characteristics of future myocardial infarctions in women with baseline high versus baseline low levels of high-sensitivity C-reactive proteinAm J Cardiol2007991500-1503. 40. Bansal S, Ridker PM. Comparison of characteristics of future myocardial infarctions in women with baseline high versus baseline low levels of high-sensitivity C-reactive protein. Am J Cardiol 2007;99:1500–1503.
41.
Jones LWHaykowsky MPituskin EN et al. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor-positive operable breast cancerOncologist2007121156-1164. 41. Jones LW, Haykowsky M, Pituskin EN, et al. Cardiovascular reserve and risk profile of postmenopausal women after chemoendocrine therapy for hormone receptor-positive operable breast cancer. Oncologist 2007;12:1156–1164.
42.
Pierce BLNeuhouser MLWener MH et al. Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivorsBreast Cancer Res Treat2009114155-167. 42. Pierce BL, Neuhouser ML, Wener MH, et al. Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat 2009;114:155–167.
43.
Fairey ASCourneya KSField CJ et al. Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: A randomized controlled trialBrain Behav Immun200519381-388. 43. Fairey AS, Courneya KS, Field CJ, et al. Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: A randomized controlled trial. Brain Behav Immun 2005;19:381–388.
44.
Bird BRSwain SM. Cardiac toxicity in breast cancer survivors: Review of potential cardiac problemsClin Cancer Res20081414-24. 44. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clin Cancer Res 2008;14:14–24.
45.
Ganz PAHussey MAMoinpour CM et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897J Clin Oncol2008261223-1230. 45. Ganz PA, Hussey MA, Moinpour CM, et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol S8897. J Clin Oncol 2008;26:1223–1230.
46.
Takkouche BCRegueira-MendezEtminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: A meta-analysisJ Natl Cancer Inst20081001439-1447. 46. Takkouche BC, Regueira-Mendez, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: A meta-analysis. J Natl Cancer Inst 2008;100:1439–1447.
47.
Eilertsen ALSandvik LSteinsvik BSandset PM. Differential impact of conventional-dose and low-dose post-menopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markersJ Thromb Haemost20086928-934. 47. Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM. Differential impact of conventional-dose and low-dose post-menopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 2008;6:928–934.
Information & Authors
Information
Published In
Journal of Women's Health
Volume 18 • Issue Number 12 • December 2009
Pages: 2041 - 2047
PubMed: 20044868
Copyright
Copyright 2009, Mary Ann Liebert, Inc.
History
Published online: 1 January 2010
Published in print: December 2009
Topics
Authors
Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.